Immunogenic composition of hepatitis C and methods of use thereof
AssigneeHawaii Biotech, Inc.
InventorsEileen T. Nakano, David E. Clements, Tom Humphreys
Life of this patent
Estimating the term…
Abstract
The present invention provides truncated HCV E2 polypepides. The invention HCV E2 polypeptides lack the HVR1 region that provides immune protection against HCV. The present invention also provides immunogenic compositions of such polypeptides and the methods of use thereof.
Claims38
A secreted polypeptide comprising:
- a hepatitis C virus (HCV) E2 polypeptide, lacking all or a portion of its membrane spanning domain such that said E2 polypeptide is capable of secretion into growth medium when expressed recombinantly in a host cell, and further comprising a deletion in at least a portion of its N-terminus ending at about amino acid residue 411, numbered with reference to the HCV E2 amino acid sequence (SEQ ID NO:9).
A secreted polypeptide comprising:
- a hepatitis C virus (HCV) E2 polypeptide, lacking all or a portion of its membrane spanning domain such that said E2 polypeptide is capable of secretion into growth medium when expressed recombinantly in a host cell, wherein said E2 polypeptide lacks at least a portion of its C-terminus beginning at about amino acid residue 662 and at least a portion of its N-terminus ending at about amino acid residue 411, numbered with reference to the HCV E2 amino acid sequence (SEQ ID NO:9).
A method of producing anti-HCV antibodies comprising administering to a mammal an effective amount of an immunogenic polypeptide composition comprising a hepatitis C virus (HCV) E2 polypeptide, lacking all or a portion of its membrane spanning domain such that said E2 polypeptide is capable of secretion into growth medium when expressed recombinantly in a host cell, and further comprising a deletion in at least a portion of its N-terminus ending at about amino acid residue 411, numbered with reference to the HCV E2 amino acid sequence (SEQ ID NO:9).
A secreted polypeptide comprising:
- a hepatitis C virus (HCV) E2 polypeptide, lacking all or a portion of its membrane spanning domain such that said E2 polypeptide is capable of secretion into growth medium when expressed recombinantly in a host cell, wherein said E2 polypeptide lacks at least a portion of its C-terminus beginning at about amino acid residue 662 and at least a portion of its N-terminus ending at about amino acid residue 411, numbered with reference to the HCV E2 amino acid sequence (SEQ ID NO:9), wherein said polypeptide is produced recombinantly in insect host cells.
Dependencies are inferred from the claim text.